In contrast to CSF findings, significantly downregulated VIP levels have been identified in the serum of patients irrespective of the MS clinical subtype (i.e., RRMS or progressive MS cases); furthermore, rising levels of VIP were positively associated with worsening disability and history of relapse [61]. This evidence concerns the gene VIP and myeloid sarcoma.